---

Contract development and manufacturing organization (CDMO), Lonza has added a new facility for quality control and bioanalytics at its Drug Product Services (DPS) in Basel, Switzerland. This move is expected to allow the company to expedite product delivery, which is essential for its clients to advance through clinical development and commercialization.

Peter Droc, Head of Drug Product Services, stated that the new bioanalytics and quality control facility would allow Lonza to offer clients essential manufacturing services for the delivery of life-saving medications, as the demand for pharma product manufacture keeps rising.

---

READ ALSO: Lonza Secures Long-Term Agreement to Supply Critical Cell Therapy for Sickle Cell Treatment

---

To meet market demand for early and late-stage clinical and commercial drug product quality control, the proposed expansion will comprise 6000m2 of cutting-edge labs and office space. The new facility enhances the drug product capabilities already provided by the Stücki Technology Park in Basel (CH) and enables DPS to increase its capacity for the development and testing of parenteral dosage forms.

“Expanding Lonza’s drug product capacity is a key enabler of our wider Biologics strategy to offer drug developers a seamless solution across modalities, from early development to drug substance and drug product manufacture,” emphasized Droc.

---

Did you find this insightful? Subscribe for more.

---